IPO

GENFIT S.A. announced its intention to issue and sell, subject to market and other conditions, 5,000,000 of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of ordinary shares in Europe and other countries outside of the US.

Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo (AM-125) and antipsychotic-induced weight gain (AM-201)

Koligo Therapeutics a regenerative medicine and 3D bio-printing company to list on the ASX under the stock ticker “KOL”.

Interim data from all patients enrolled in ongoing L-MIND trial of MOR208 in combination with lenalidomide in relapsed/refractory DLBCL confirm activity suggested by earlier data cuts

In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.

For BioNTech, the IPO will follow a funding round that brought about $270 million into the coffers of the privately-held company.

A turnover of €47.4 million, including €37.1 million related to the partnership signed with the Chinese company Tonghua Dongbao and €10.3 million following the judgment rendered in favor of Adocia in the first phase of the arbitration against Eli Lilly & Co

Auris Medical Holding AG announced that it will provide a business update and report its financial results for the fourth quarter and full year 2018 on Thursday, March 14, 2019.

Neos Therapeutics, Inc. today announced that it will report its fourth quarter and year-end 2018 financial results prior to the opening of U.S. financial markets on Thursday, March 14, 2019.

Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of Floating Rate Senior Notes due 2021, €1,500,000,000 principal amount of 0.000% Senior Notes due 2021, €1,500,000,000 principal amount of 0.375% Senior Notes due 2023, €1,500,000,000 principal amount of 1.125% Senior Notes due 2027, €1,000,000,000 principal amount of 1.625% Senior Notes due 2031 and €1,000,000,000 principal amount of 2.250% Senior Notes due 2039.